Supplemental Table 1. Assay Performance Characteristics in Human Plasma

	Assay Range (ng/mL)	Nominal Concentration				
			Low QC	Mid QC	High QC	ULOQ QC
			3 ng/mL	300 ng/mL	750 ng/mL	
Omeprazole	1–1000	% CV	5.8	3.1	4.1	ND
		% Bias	5.3	4.7	–1.1	ND
5-Hydroxyomeprazole		% CV	4.5	3.3	3.6	ND
		% Bias	–0.7	2.0	–1.7	ND
			0.3 ng/mL	18 ng/mL	78 ng/mL	
Midazolam	0.1–100	% CV	3.3	5.9	2.6	ND
		% Bias	–2.3	–1.7	–0.9	ND
1-Hydroxymidazolam		% CV	8.7	4.4	2.8	ND
		% Bias	–0.7	–2.8	–3.1	ND
			0.15 ng/mL	4 ng/mL	39 ng/mL	
Dextromethorphan	0.05–50	% CV	3.5	2.0	1.9	ND
		% Bias	–1.3	–0.3	1.0	ND
Dextrorphan		% CV	3.1	1.7	1.5	ND
		% Bias	2.7	1.8	2.1	ND
			60 ng/mL	7900 ng/mL	15,800 ng/mL	
Caffeine	20–20,000	% CV	7.8	2.1	2.6	ND
		% Bias	–0.3	–2.3	–2.5	ND
Paraxanthine		% CV	4.3	3.7	2.9	ND
		% Bias	1.5	0.5	–0.6	ND
			3 ng/mL	20 ng/mL	80 ng/mL	100 ng/mL
Lisdexamfetamine	1–100	% CV	7.8	8.8	4.6	4.0
		% Bias	–3.7	–2.5	–1.3	–0.1
			6 ng/mL	40 ng/mL	160 ng/mL	200 ng/mL
d-Amphetamine	2–200	% CV	5.1	7.8	5.3	3.4
		% Bias	–7.2	–3.5	–0.6	0.5

CV=coefficient of variation; ND=not determined; QC=quality control; ULOQ=upper limit of quantification.

Supplemental Table 2. Baseline Demographic Characteristics, Safety Analysis Set

	Cooperstown Cocktail Alone (Period 1)/ Cooperstown Cocktail+LDX 70 mg (Period 2) (n=15)	Cooperstown Cocktail+LDX 70 mg (Period 1)/ Cooperstown Cocktail Alone (Period 2) (n=15)
Age, y		
Mean ± SD	35.0±8.32	36.2±7.71
Range	21–45	19–45
Sex, n (%)		
Male	13 (86.7)	5 (33.3)
Female	2 (13.3)	10 (66.7)
Race, n (%)		
White	13 (86.7)	13 (86.7)
Black or African American	2 (13.3)	2 (13.3)
Ethnicity, n (%)		
Hispanic or Latino	9 (60.0)	12 (80.0)
Not Hispanic or Latino	6 (40.0)	3 (20.0)
Mean ± SD weight, kg	83.7±11.72	72.5±15.10
Mean ± SD height, cm	175.3±9.22	167.8±10.75
Mean ± SD Body mass index, kg/m^2	27.2±2.56	25.5±3.04

LDX=lisdexamfetamine dimesylate.

Supplemental Table 3. Summary of TEAEs,[a] Safety Analysis Set

	Cooperstown Cocktail (n=30)		Cooperstown Cocktail + LDX (n=29)	
	n (%)	**Number of Events**	**n (%)**	**Number of Events**
Any TEAE	18 (60.0)	27	26 (89.7)	77
Any serious TEAE	0	0	0	0
TEAE related to study drug	18 (60.0)	27	26 (89.7)	77
TEAE leading to study discontinuation	0	0	0	0
Any severe TEAE	0	0	0	0
Preferred terms				
Insomnia	2 (6.7)	2	12 (41.4)	12
Somnolence	13 (43.3)	13	10 (34.5)	10
Dry mouth	0	0	9 (31.0)	9
Increased blood pressure	2 (6.7)	2	8 (27.6)	8
Tachycardia	0	0	5 (17.2)	5
Dizziness	4 (13.3)	4	5 (17.2)	5
Decreased appetite	0	0	4 (13.8)	4
Euphoric mood	0	0	4 (13.8)	4
Nausea	2 (6.7)	2	3 (10.3)	4
Anxiety	0	0	3 (10.3)	3
Depressed mood	0	0	3 (10.3)	3
Abdominal pain	0	0	2 (6.9)	2
Headache	2 (6.7)	2	2 (6.9)	2
Peripheral coldness	0	0	2 (6.9)	2

LDX=lisdexamfetamine dimesylate; TEAE=treatment-emergent adverse event.

[a]Participants were counted by the treatment most recently taken when the event occurred and were counted once per category per treatment.

Supplemental Table 4. Mean ± SD Change From Baseline in SBP, DBP, and Pulse Rate, Safety Analysis Set

	Cooperstown Cocktail Alone (n=30)	Cooperstown Cocktail + LDX 70 mg (n=29)
SBP, mmHg		
4 h	–0.7±12.19	8.2±10.47
8 h	2.6±7.76	16.9±12.57
12 h	1.5±10.23	13.5±12.03
24 h	–1.4±10.03	–1.3±10.11
DBP, mmHg		
4 h	1.3±8.86	6.1±8.55
8 h	1.8±7.71	10.6±10.33
12 h	0.9±8.75	7.6±9.70
24 h	3.0±10.23	2.9±8.80
Pulse rate, bpm		
4 h	–2.1±11.09	5.7±10.45
8 h	3.2±10.04	22.5±15.89
12 h	3.7±8.37	23.1±14.63
24 h	4.5±10.89	9.0±12.18

DBP=diastolic blood pressure; LDX=lisdexamfetamine dimesylate; SBP=systolic blood pressure.